Patents by Inventor Ann-Kristin Spiik

Ann-Kristin Spiik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for modulating responsiveness to steroids
    Patent number: 8569257
    Abstract: A method for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment comprises administering an oligonucleotide having the sequence formula (SEQ.?ID.?No.?18) 5?-Xm-TTCGT-Yn-3? in an effective amount to said patient and wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: October 29, 2013
    Assignee: Index Pharmaceuticals AB
    Inventors: Ann-Kristin Spiik, Robert Löfberg, Lisa Charlotta Bandholtz, Oliver Von Stein, Arezou Zargari
  • Compounds for the treatment or alleviation of edema, and methods for their use
    Patent number: 8410068
    Abstract: Isolated and substantially purified oligonucleotide compounds have been shown to be effective in reducing swelling and edema. Novel methods and substances are presented for the prevention, alleviation or treatment of edema of various aetiology.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: April 2, 2013
    Assignee: Index Pharmaceuticals AB
    Inventors: Arezou Zargari, Lars-Goran Axelsson, Ann-Kristin Spiik, Nikolai Kouznetsov
  • Method for Modulating Responsiveness to Steroids
    Publication number: 20120172420
    Abstract: A method for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment comprises administering an oligonucleotide having the sequence formula (SEQ.?ID.?No.?18) 5?-Xm-TTCGT-Yn-3? in an effective amount to said patient and wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated.
    Type: Application
    Filed: March 1, 2012
    Publication date: July 5, 2012
    Inventors: Ann-Kristin Spiik, Robert Löfberg, Lisa Charlotta Bandholtz, Oliver Von Stein, Arezou Zargari
  • Method for modulating responsiveness to steroids
    Patent number: 8148341
    Abstract: The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of an oligonucleotide having the sequence 5?-Xm-TTCGT-Yn-3? to 5 said patient, wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated. The invention also encompasses the use of said oligonucleotide for the manufacture of pharmaceuticals.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: April 3, 2012
    Assignee: InDex Pharmaceuticals AB
    Inventors: Ann-Kristin Spiik, Robert Löfberg, Lisa Charlotta Bandholtz, Oliver Von Stein
  • Novel Compounds for the Treatment or Alleviation of Edema, and Methods for their Use
    Publication number: 20100240736
    Abstract: Isolated and substantially purified oligonucleotide compounds have been shown to be effective in reducing swelling and edema. Novel methods and substances are presented for the prevention, alleviation or treatment of edema of various aetiology.
    Type: Application
    Filed: October 2, 2008
    Publication date: September 23, 2010
    Inventors: Arezou Zargari, Lars-Goran Axelsson, Ann-Kristin Spiik, Nikolai Kouznetsov
  • Method for Modulating Responsiveness to Steroids
    Publication number: 20080318885
    Abstract: The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of an oligonucleotide having the sequence 5?-Xm-TTCGT-Yn-3? to 5 said patient, wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated. The invention also encompasses the use of said oligonucleotide for the manufacture of pharmaceuticals.
    Type: Application
    Filed: June 30, 2006
    Publication date: December 25, 2008
    Inventors: Ann-Kristin Spiik, Robert Lofberg, Lisa Charlotta Bandholtz, Oliver Von Stein